Roughly half a year after the close of its deal to acquire Bayer spinout AiCurus, Asahi Kasei’s $920 million bet has paid off ...

Most manufacturers know Inmar for pharmacy returns and consumer drug takeback programs. | Emily Welker explains how retail ...

Everyone talks about AI as an efficiency engine. But according to /prompt CEO Paul Dyer, the technology’s greatest impact may ...

The pharmaceutical patient journey has always been complex, but today's media environment presents more touchpoints than ever ...

Life sciences organizations have invested heavily in data and analytics, yet timely decision making remains a challenge. | ...

Less than four years after returning to Bausch + Lomb to lead the eye health company following its split from Bausch Health, ...

Invenra has created playing cards featuring artwork by people affected by cancer as it seeks biopharma buy-in for its ...

Livmarli significantly improved severe itching caused by rare liver diseases. With the phase 3 win in hand, Mirum is looking for a third indication from the FDA early next year.

AI is transforming healthcare by making guidelines, clinical trial data and emerging research more accessible than ever. | AI delivers information. Peer validation delivers confidence. Learn how HCP ...

General-purpose AI can identify broad patterns, but clinical development demands models that understand the complex relationships within life sciences data. In this sponsored episode of The Top Line, ...

Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...

All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where ...